Wegovy and Heart Failure (HFpEF): What the Evidence Says

Heart failure with preserved ejection fraction — HFpEF — is the kind of heart failure where the heart still squeezes normally but has become stiff and can't relax and fill properly. It's strongly tied to obesity, it's notoriously hard to treat, and for years it had very few therapies that meaningfully improved how patients actually feel. So when trials showed that Wegovy (semaglutide 2.4 mg) improved symptoms and physical function in people with obesity-related HFpEF, it was genuinely big news. But the story is easy to oversell. This guide walks through exactly what the STEP-HFpEF trials found, what they did not find, why Europe updated the label while the US FDA has not approved a HFpEF use, and what that means for you. It is general education, not medical advice for your situation.

The single most important distinction up front: these trials proved that semaglutide makes people with obesity-related HFpEF feel and function better — fewer symptoms, more exercise capacity. They were not designed or powered to prove that it makes people live longer or keeps them out of the hospital (so-called "hard outcomes"). Those are different questions, and conflating them is the most common way this story gets distorted. We'll keep symptom benefit and hard outcomes strictly separate throughout.

A grounding fact first. Wegovy and Ozempic are the same molecule — semaglutide — sold under two brand names for two different approved uses (chronic weight management for Wegovy, diabetes for Ozempic). We unpack that in Ozempic vs Wegovy: same drug, different label. The HFpEF evidence sits on the Wegovy side, at the higher 2.4 mg weekly weight-management dose, not the Ozempic diabetes doses.

The STEP-HFpEF trials: what they actually showed

The evidence rests on two companion randomized trials. STEP-HFpEF, published in the New England Journal of Medicine in 2023, enrolled 529 adults who had HFpEF (ejection fraction ≥45%) and obesity (BMI ≥30) but did not have diabetes. STEP-HFpEF DM, published in 2024, ran the same design in 616 adults who had obesity-related HFpEF and type 2 diabetes. In both, participants were randomized to once-weekly semaglutide 2.4 mg or placebo for one year, on top of usual care¹².

Both trials shared two co-primary endpoints, and both are about how patients felt and functioned, not survival:

• •Symptoms and quality of life, measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) — a validated 0–100 scale where higher is better.
• •Body weight — change from baseline.

In the original STEP-HFpEF (no diabetes), semaglutide improved the KCCQ-CSS by about 16.6 points versus 8.7 on placebo — a roughly 7.8-point advantage, which is clinically meaningful for how patients rate their breathlessness and daily limitations. Weight fell about 13.3% versus 2.6% on placebo. The drug also improved a key functional measure, the 6-minute walk distance (6MWD), and lowered the inflammation marker CRP¹.

In STEP-HFpEF DM (with diabetes), the pattern held but was somewhat blunted by the diabetes: the KCCQ-CSS improved about 13.7 versus 6.4 points (a ~7.3-point advantage), and weight fell about 9.8% versus 3.4% — less weight loss than in the non-diabetic trial, consistent with the general pattern that people with type 2 diabetes lose somewhat less weight on these drugs².

Symptom benefit vs hard outcomes: the line that matters

Here is the distinction the headlines blur. STEP-HFpEF and STEP-HFpEF DM were symptom-and-function trials. Their co-primary endpoints were a quality-of-life score and weight — not death, and not heart-failure hospitalization. Each enrolled only a few hundred people for one year, which is far too small and too short to prove a mortality or hospitalization benefit. So the honest statement is: semaglutide is shown to improve symptoms, quality of life, and exercise capacity in obesity-related HFpEF — it is not (yet) shown to reduce deaths or hospitalizations in a dedicated, adequately powered outcomes trial.

There are supportive signals on the harder questions, but they should be read as exactly that — signals, not proof:

• •A 2024 JACC analysis of pooled STEP-HFpEF data found semaglutide improved measures of cardiac structure and function (such as reduced left-atrial size and lower filling pressures), offering a plausible mechanism for why people felt better³.
• •A 2024 Lancet pooled analysis combined STEP-HFpEF, STEP-HFpEF DM, and the much larger SELECT and FLOW outcomes trials and reported fewer heart-failure events with semaglutide in people with heart failure and a preserved or mildly reduced ejection fraction⁴. This is encouraging, but a post-hoc pooled analysis across trials with different designs is hypothesis-generating, not the same as a single trial built to answer the hospitalization-and-death question.

So the evidence ladder is honest and specific: strong for symptoms and function, moderate/mechanistic for cardiac remodeling, and suggestive-only for hard clinical outcomes. We apply that same discipline to the broader cardiovascular data — where the SELECT trial did prove hard-outcome benefit, but in a different population — in do Wegovy & Ozempic protect the heart?.

Is it just weight loss — or something more?

A fair question: since obesity drives HFpEF, is the benefit simply "lose weight, feel better"? Weight loss is clearly a major part of it — the trials were built around an obesity-related HFpEF phenotype, and weight fell substantially. But the data hint at more than weight alone. The symptom improvement appeared to exceed what weight loss by itself would predict, and semaglutide also lowered CRP (an inflammation marker) and improved cardiac filling measures¹³. GLP-1 receptor agonists plausibly reduce the systemic inflammation and congestion that make stiff hearts symptomatic — effects that ride alongside, not purely through, the pounds lost. The exact split between "weight" and "direct" effects is still being worked out; the honest summary is that it's likely both.

The regulatory split: EU updated the label, the US FDA has not approved it

This is where many readers get the wrong impression, so the geography matters.

In Europe, the regulator acted on the STEP-HFpEF data. In September 2024, the EMA's scientific committee (CHMP) adopted a positive opinion recommending a Wegovy label update to reflect that it can reduce heart-failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF⁵. Read that wording precisely: the EU label change is about symptoms and function — exactly what the trials measured — not a claim that the drug reduces deaths or hospitalizations.

In the United States, there is no FDA-approved HFpEF indication for Wegovy as of June 2026. The path has been bumpy: Novo Nordisk initially withdrew its FDA filing for the HFpEF use after feedback from the agency, then resubmitted in early 2025 with additional data (including the FLOW kidney-outcomes trial and the pooled heart-failure analysis), and a decision has been pushed into 2026⁶. If it is eventually approved, Wegovy would be the first GLP-1 cleared for HFpEF in the US — but that has not happened yet. (Regulatory timelines move; confirm the current status with a clinician or the official label before acting on it.)

So the accurate framing is: proven symptom and function benefit in trials → EU label reflects it → US FDA approval is still pending, not granted. Anyone telling you "the FDA approved Wegovy for heart failure" is ahead of the facts.

Where this fits the wider semaglutide story

HFpEF is one of several organs where semaglutide has run its own dedicated trial, and the pattern is always the same — each benefit belongs to the population actually studied, and the strength of the claim depends on what the trial was built to measure:

• •Heart (SELECT): semaglutide cut major cardiovascular events ~20% in people with established cardiovascular disease plus obesity, without diabetes — a hard-outcome win, now an FDA cardiovascular indication. See do Wegovy & Ozempic protect the heart?.
• •Kidney (FLOW): semaglutide slowed kidney decline in people with type 2 diabetes and chronic kidney disease — also a hard-outcome win and an FDA indication. See Ozempic for kidney disease: what the FLOW trial showed.
• •Liver (MASH): semaglutide became the first GLP-1 approved for fatty-liver disease. See Wegovy for MASH (fatty liver): the new FDA approval.
• •HFpEF (STEP-HFpEF): a symptom-and-function win — EU label updated, US approval pending.

One more honest pairing: semaglutide modestly raises resting heart rate even as it eases HFpEF symptoms — a separate, labeled class effect that coexists with the benefit, explained in does Wegovy or Ozempic raise heart rate?.

The honest bottom line

What's proven: In adults with obesity-related HFpEF, semaglutide 2.4 mg (Wegovy) improves heart-failure symptoms, quality of life, and exercise capacity versus placebo over a year — in two randomized trials, with and without type 2 diabetes¹². Europe's regulator has updated the Wegovy label to reflect this symptom-and-function benefit⁵.

What's not (yet) proven: That semaglutide reduces deaths or heart-failure hospitalizations in HFpEF — these trials weren't built to answer that, and the supportive pooled signal is hypothesis-generating, not definitive⁴. That it helps non-obese HFpEF (the trials required obesity). And in the US, there is no FDA-approved HFpEF indication as of mid-2026 — the application is pending, not granted⁶.

The framing that matters: This is a prescription-only medicine with real benefits and real risks (gastrointestinal effects, gallbladder disease, and more). The HFpEF symptom benefit makes it a promising tool for the right person — someone with obesity-related HFpEF whose clinician is weighing it against their whole picture — not a proven life-extending heart-failure cure, and not (in the US) an approved heart-failure drug. Whether it fits you is a conversation for your clinician.

For the complete picture of how semaglutide works, what results to expect, and the full safety profile, start with our pillar guide, Semaglutide: how it works, results & side effects. And if you're weighing providers, our editorial ranking is at the best semaglutide options, rated.